Rituximab (Rituxan) — Clinical FAQs

Question 1

What is Rituximab FDA-approved to treat?

Accepted Answer

Rituximab is FDA-approved for the following oncology indications: 1. Non-Hodgkin lymphoma — relapsed/refractory, low-grade/follicular, CD20-positive, B-cell; first-line follicular with chemotherapy 2. CLL — first-line with fludarabine and cyclophosphamide (RFC) 3. Rheumatoid arthritis (off-label in oncology context) 4. Granulomatosis with polyangiitis (GPA/Wegener's) 5. Microscopic polyangiitis (and 1 additional indications).

Question 2

How does Rituximab work (mechanism of action)?

Accepted Answer

Chimeric anti-CD20 monoclonal antibody (IgG1κ). Binds specifically to CD20 antigen on pre-B and mature B lymphocytes (but not on stem cells or plasma cells). Causes B-cell lysis via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct induction of apoptosis.

Question 3

How is Rituximab administered?

Accepted Answer

Rituximab is administered Intravenous (IV) or Subcutaneous (SC). IV infusion: initial rate 50 mg/h for first infusion, escalate by 50 mg/h every 30 min to max 400 mg/h if tolerated.

Question 4

What are the most common side effects of Rituximab?

Accepted Answer

The most commonly reported side effects of Rituximab (≥10% incidence) include: Infusion reactions (fever, chills, rigors, hypotension, urticaria — first infusion), Immunosuppression/lymphopenia (B-cell depletion), Infections (bacterial, fungal, viral), Nausea, Fatigue and others (6 total). Consult your oncologist for complete prescribing information.

Question 5

Does Rituximab have a black box warning?

Accepted Answer

Yes. Rituximab carries FDA black box warning(s) regarding: 1. Fatal infusion reactions: cytokine release syndrome (CRS) and rapid tumor destruction during or within 24 hours of infusion; most deaths occur with first infusion. 2. Tumor lysis syndrome (TLS): severe and fatal TLS within 12–24 hours of first infusion, especially with high tumor burden; aggressive prophylaxis required. 3. Severe mucocutaneous reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, paraneoplastic pemphigus — some fatal. 4. Progressive multifocal leukoencephalopathy (PML): JC virus-induced, often fatal; discontinue rituximab and any concomitant chemotherapy. 5. Hepatitis B virus reactivation: fatal fulminant hepatitis reported; screen all patients before initiating therapy.

Question 6

Is Rituximab safe during pregnancy?

Accepted Answer

Rituximab pregnancy safety: Category C — B-cell depletion in newborns if exposed during pregnancy; avoid unless benefit outweighs risk.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Rituximab — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms